Αρχική World News FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated... World News FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer Από Ogkologos - 28 Οκτωβρίου, 2026 390 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the SERENA-6 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Trastuzumab Deruxtecan Shows High Intracranial Response Rate in Patients with Active... 9 Αυγούστου, 2022 TAT 2021 Honorary Award: A Recognition in Cancer Drug Development to... 16 Φεβρουαρίου, 2021 Bladder Cancer Trial Finds Extended Lymph Node Surgery Doesn’t Improve Survival 6 Νοεμβρίου, 2024 NHL Team Surprises Big Fan Who Spent Breast Cancer Treatment Performing... 22 Ιανουαρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Nirogacestat May Offer Hope to People with Desmoid Tumors Complete Cancer Prevalence in Europe in 2020 Reveals an Increased Proportion... Garbage Men Finally Meet Cancer-Free Toddler After Bonding From Afar Dr Ian Walker on Smoking: ‘The killer behind the counter’